Analyst Note
| Aaron Degagne |Teleflex had a mixed fourth quarter with sales across most product lines still below a prepandemic baseline, though the firm had some pockets of relative strength in vascular access and interventional urology. We are maintaining our $192 fair value estimate and no-moat rating, and shares remain overvalued, in our view.